
|Articles|January 1, 2005
Trial to study potential MMD treatment
Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Q&A: As DMEI turns 50, R. Michael Siatkowski, MD, MBA, looks to the future
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
5

















































.png)


